Tx Advances SCLC Module

CME

Recent Therapeutic Advances in Advanced SCLC

Physicians: Maximum of 0.75 AMA PRA Category 1 Credit

Released: March 26, 2024

Expiration: March 25, 2025

Carl M. Gay
Carl M. Gay, MD, PhD

Activity

Progress
1 2
Course Completed

References

 

  1. Koinis F, Kotsakis A, Georgoulias V. Small cell lung cancer (SCLC): no treatment advances in recent years. Transl Lung Cancer Res. 2016;5:39-50.
  2. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: small-cell lung cancer. v.2.2024. nccn.org. Accessed March 19, 2024.
  3. Waqar SN, Morgensztern D. Treatment advances in small cell lung cancer (SCLC). Pharmacol Ther. 2017;180:16-23.
  4. Atezolizumab [prescribing information]. South San Francisco, CA: Genentech, Inc; 2023.
  5. Durvalumab [prescribing information]. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2023.
  6. Horn L, Mansfield AS, Szczesna A, et al. First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer. N Engl J Med. 2018;379:2220-2229.
  7. Liu S, Dziadziuszko R, Sugawara S, et al. Five-year survival in patients with ES-SCLC treated with atezolizumab in IMpower133: IMbrella A extension study results. Presented at: 2023 World Conference on Lung Cancer; September 9-12, 2023. Abstract OA01.04.
  8. Paz-Ares L, Chen Y, Reinmuth N, et al. Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN. ESMO Open. 2022;7:100408.
  9. Paz-Ares L, Dvorkin M, Chen Y, et al. Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial. Lancet. 2019;394:1929-1939.
  10. Raso MG, Bota-Rabassedas N, Wistuba, II. Pathology and classification of SCLC. Cancers (Basel). 2021;13.
  11. National Comprehensive Cancer Network. Clinical practice guidelines in oncology: non-small-cell lung cancer. v.3.2024. nccn.org. Accessed March 19, 2024.
  12. Rudin CM, Brambilla E, Faivre-Finn C, Sage J. Small-cell lung cancer. Nat Rev Dis Primers. 2021;7:3.
  13. George J, Lim JS, Jang SJ, et al. Comprehensive genomic profiles of small cell lung cancer. Nature. 2015;524:47-53.
  14. Gay CM, Stewart CA, Park EM, et al. Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities. Cancer Cell. 2021;39:346-360 e347.
  15. Heeke S, Gay CM, Estecio MR, et al. Tumor- and circulating-free DNA methylation identifies clinically relevant small cell lung cancer subtypes. Cancer Cell. 2024;42:225-237 e225.
  16. Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019;12:61.
  17. Carvajal-Hausdorf D, Altan M, Velcheti V, et al. Expression and clinical significance of PD-L1, B7-H3, B7-H4 and TILs in human small cell lung cancer (SCLC). J Immunother Cancer. 2019;7:65.
  18. Inamura K, Yokouchi Y, Kobayashi M, et al. Association of tumor TROP2 expression with prognosis varies among lung cancer subtypes. Oncotarget. 2017;8:28725-28735.
  19. Giffin MJ, Cooke K, Lobenhofer EK, et al. AMG 757, a half-life extended, DLL3-targeted bispecific T-cell engager, shows high potency and sensitivity in preclinical models of small-cell lung cancer. Clin Cancer Res. 2021;27:1526-1537.
  20. Ahn MJ, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063-2075.
  21. Cosenza M, Sacchi S, Pozzi S. Cytokine release syndrome associated with T-cell-based therapies for hematological malignancies: pathophysiology, clinical presentation, and treatment. Int J Mol Sci. 2021;22.
  22. Omer MH, Shafqat A, Ahmad O, Alkattan K, Yaqinuddin A, Damlaj M. Bispecific antibodies in hematological malignancies: a scoping review. Cancers (Basel). 2023;15.
  23. Tocilizumab [prescribing information]. South San Francisco, CA: Genentech, Inc; 2022.
  24. Wermke M. Phase I dose escalation trial of the DLL3/CD3 Igg-like T cell engager BI 764532 in patients with DLL3+ tumors: focus on SCLC. Presented at: 2023 World Conference on Lung Cancer; September 9-12, 2023. Abstract OA01.05.
  25. Metrangolo V, Engelholm LH. Antibody-drug conjugates: the dynamic evolution from conventional to next-generation constructs. Cancers (Basel). 2024;16.
  26. Johnson M, Awad M, Koyama T, et al. Ifinatamab deruxtecan (I-DXd; DS-7300) in patients with refractory SCLC: a subgroup analysis of a phase 1/2 study. Presented at: 2023 International Association for the Study of Lung Cancer World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.05.
  27. Shimizu T, Sands J, Yoh K, et al. First-in-human, phase I dose-escalation and dose-expansion study of trophoblast cell-surface antigen 2-directed antibody-drug conjugate datopotamab deruxtecan in non-small-cell lung cancer: TROPION-PanTumor01. J Clin Oncol. 2023;41:4678-4687.
  28. Tarantino P, Modi S, Tolaney SM, et al. Interstitial lung disease induced by anti-ERBB2 antibody-drug conjugates: a review. JAMA Oncol. 2021;7:1873-1881.
  29. Lisberg A, Ahn MJ, Paz-Ares L, et al. Datopotamab deruxtecan (Dato-DXd) vs docetaxel in previously treated advanced/metastatic (adv/met) non-small cell lung cancer (NSCLC): results of the randomized phase III study TROPION-Lung01. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstract LBA12.
  30. Goldenberg DM, Cardillo TM, Govindan SV, Rossi EA, Sharkey RM. Trop-2 is a novel target for solid cancer therapy with sacituzumab govitecan (IMMU-132), an antibody-drug conjugate (ADC). Oncotarget. 2015;6:22496-22512.
  31. Goldenberg DM, Sharkey RM. Antibody-drug conjugates targeting TROP-2 and incorporating SN-38: A case study of anti-TROP-2 sacituzumab govitecan. MAbs. 2019;11:987-995.
  32. Liu X, Deng J, Yuan Y, et al. Advances in Trop2-targeted therapy: Novel agents and opportunities beyond breast cancer. Pharmacol Ther. 2022;239:108296.
  33. Sacituzumab govitecan [prescribing information]. Foster City, CA: Gilead Sciences; 2023.
  34. Heist RS, Guarino MJ, Masters G, et al. Therapy of advanced non-small-cell lung cancer with an SN-38-anti-TROP-2 drug conjugate, sacituzumab govitecan. J Clin Oncol. 2017;35:2790-2797.
  35. Cho BC, Dols MC, Reyes Cabanillas R, et al. Sacituzumab govitecan + pembrolizumab in 1L metastatic non-small cell lung cancer: Preliminary results of the EVOKE-02 study. Presented at: 2023 World Conference on Lung Cancer; September 9-12, 2023. Abstract OA05.04.
  36. Dowlati A, Cervantes A, Babu S, et al. Sacituzumab govitecan as second-line treatment for extensive stage small cell lung cancer. Presented at: European Society for Medical Oncology Congress 2023; October 20-24, 2023. Abstr 199MO.
  37. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Onncology clinical practice guideline. J Clin Oncol. 2018; 36: 1714–1768.